ClinicalTrials.gg
CompletedNCT03387956Updated Jun 6, 2018

Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting

An interventional study of Intrathecal atropine and dexamethasone in Postoperative Nausea, sponsored by Assiut University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2017, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing dexamethasone in Postoperative Nausea and Vomiting — 10 open to participants now, 11 under way, 2 of them phase 3. Dexamethasone · Postoperative Nausea and Vomiting.

Enrollment
42nd of 82
120 · median 121
Started
2017
with 5 others
No phase
24 of 82
5 open now
Registered
45th of 82
by date
Lead sponsor
3 of 82
Assiut University

Among the 82 studies testing dexamethasone in Postoperative Nausea and Vomiting, this one is the 42nd largest by enrollment, is one of 6 that started in 2017, is one of 24 with no phase, and was the 45th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

10 of the 82 studies testing dexamethasone in Postoperative Nausea and Vomiting are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing dexamethasone in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

optimal postoperative pain control with intrathecal morphine, with proper prevention of postoperative nausea and vomiting. Dexamethasone, and or atropine could offer some protection against nausea and vomiting.

Read the detailed description

One of the gold standards for analgesia following cesarean delivery is intrathecal morphine, which is not devoid of complications namely postoperative nausea and vomiting. We evaluated the antiemetic effect of intravenous dexamethasone combined with intrathecal atropine after cesarean delivery under spinal bupivacaine plus morphine anesthesia.

03

Conditions studied

  • Postoperative Nausea

Keywords

  • Postoperative Nuasea
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females
  • 18-40 years of age
  • elective cesarean delivery under bupivacaine spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • renal disease
  • preeclampsia
  • liver disease
  • cardiac disease
  • Coagulopathy
  • chronic cough
  • nausea
  • vomiting
  • patient refusal
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Atropine group

    Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.

    Drug: Intrathecal atropine

  • Active comparator
    Dexamethasone group

    Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).

    Drug: dexamethasone

  • Active comparator
    Dexamethasone and Atropine group

    Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.

    Drug: Intrathecal atropine · Drug: dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. postoperative nausea

    Monitoring scale of nausea and vomiting

    Time frame: 24 hours

07

Study locations

1 site
  • Emad Zarief Kamel Said
    Assiut, 71111, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jul 2017, 4 months.

Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 4 months is below that.

Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Jan 2, 2018
StartActual
Mar 20, 2017
Primary completionActual
Jul 28, 2017
CompletionActual
Aug 10, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03387956
Lead sponsor
Assiut University
Responsible party
Emad Zarief , MD (Dr, Assiut University) — Principal investigator
First posted
Jan 2, 2018
Start date
Mar 20, 2017
Primary completion
Jul 28, 2017
Completion
Aug 10, 2017
Last update
Jun 6, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atropine · Dexamethasone

Start the discussion